A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN, PLACEBO-CONTROLLED, PARALLEL GROUP, DOSE-RANGING STUDY OF PF-07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY

Primary Objective

To study a new anti-obesity medication

Is This Study For You?

Let's Get Started!

Description

To study effectiveness, safety and tolerability of a new investigational medication (PF-07976016) in adults with obesity

Details
Age
Adult
Eligibility
18-74 years old; BMI of 30 or greater; Do not have type 1 or type 2 diabetes; Have not taken any weight loss medications in last 12 weeks
Locations

Anschutz Health and Wellness
Outpatient CTRC

Principal Investigator
Photograph of Dan Bessesen

Dan Bessesen

Study ID

Protocol Number: 24-2153

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers